The BRILLIANCE phase 1/2 clinical trial is investigating gene-editing techniques using CRISPR-Cas9 to delete the mutation in the CEP290 gene that is responsible for destroying light-sensing cells in the retina.
Learn more about inherited retinal diseases.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Donny W. Suh. Fast Five Quiz: Management of Inherited Retinal Diseases - Medscape - Apr 27, 2022.